Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Lanier Biotherapeutics receives U.S. patent for IL-25 binding molecules

Lanier Biotherapeutics announced that the United States Patent and Trademark Office has issued U.S. Patent 11,492,397, entitled, “Neutralizing Monoclonal Antibodies to IL-25 and Uses Thereof.” The patent covers...

November 14, 2022

Developments

Lantheus, POINT Biopharma to commercialize PNT2002 & PNT2003

Lantheus Holdings (NASDAQ:LNTH) and POINT Biopharma Global (NASDAQ:PNT) announced a set of strategic collaboration agreements in which Lantheus would license exclusive worldwide rights to POINT’s PNT2002 and PNT2003...

November 14, 2022

Developments

Oramed to commercialize oral insulin in Korea with Medicox

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) signed an exclusive commercial distribution agreement for the Republic of Korea with Medicox, an emerging biotech company with proven partnerships in the Korea. The agreement...

November 14, 2022

Developments

CytoSorbents appears to validate Sigyn’s therapeutic strategy

CytoSorbents (NASDAQ:CTSO) has received a research grant from a division of the NIH to test the ability of its existing polymers to remove cytokines and lipopolysaccharide (LPS) endotoxin from septic porcine plasma, a...

November 10, 2022

Developments

IntelGenx in feasibility, development agreement for CBD-infused VetaFilm for pets

IntelGenx (TSX:IGX; OTCQB:IGXT) entered into a feasibility study and development agreement with an undisclosed animal health company focused on advancing a VetaFilm-based oral film formulation containing CBD for use in...

November 9, 2022

Developments

Hepion to present rencofilstat’s poly-indication potential at antifibrotic summit

Hepion Pharmaceuticals’ (NASDAQ:HEPA) chief scientific officer, Daren Ure, Ph.D., will present data highlighting the poly-indication potential of the company’s lead drug candidate, rencofilstat, at the upcoming 6th...

November 7, 2022

Developments

Hepion to present 2 posters at upcoming AASLD liver meeting

Hepion Pharmaceuticals (NASDAQ:HEPA) is presenting two poster presentations highlighting its lead drug candidate, rencofilstat, at the Liver Meeting 2022, to be hosted by the American Association for the Study of Liver...

November 2, 2022

Developments

Rhythm to launch Phase 3 hypothalamic obesity trial in early 2023

Rhythm Pharmaceuticals (NASDAQ:RYTM) plans to initiate a Phase 3 clinical trial in acquired hypothalamic obesity in early 2023, following recent discussions with the FDA. The Phase 3 clinical trial will enroll 120...

November 2, 2022

Developments

IntelGenx files for U.S. oral film patent improving cannabinoid onset of action

IntelGenx (TSX:IGX; OTCQB:IGXT) filed a new provisional patent application with the United States Patent and Trademark Office (USPTO) entitled, “Advanced Oral Film Formulations.” The patent application...

November 2, 2022

Developments

Atossa to acquire stake in Dynamic Cell Therapies

Atossa Therapeutics (NASDAQ:ATOS) is acquiring 19.99% of the capital stock of closely-held Dynamic Cell Therapies for $2-million, in addition to $3-million previously paid to Dynamic, “This investment in Dynamic...

November 1, 2022

Developments

Rhythm Pharma gets FDA breakthrough status in hypothalamic obesity

Rhythm Pharmaceuticals’ (NASDAQ:RYTM) setmelanotide received breakthrough therapy designation from the FDA for the treatment of hypothalamic obesity. Hypothalamic obesity is a rare, acquired form of extreme obesity that...

November 1, 2022

Developments

OpSens starts SavvyWire study in Europe

OpSens (TSX:OPS; OTCQX:OPSSF) announced the successful completion of the first cases in a clinical study, named SAFE-TAVI, studying SavvyWire left ventricular rapid pacing in transcatheter aortic valve replacement...

October 26, 2022

Developments

Hepion Pharmaceuticals Phase 2a AMBITION results published

The peer-reviewed journal, Hepatology Communications, has published a paper by Harrison et al. entitled, “Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in...

October 26, 2022

Developments

IntelGenx receives FDA GDUFA date for partnered buprenorphine buccal film

IntelGenx’s (TSX:IGX; OTCQB:IGXT) previously undisclosed development candidate, buprenorphine buccal film, for which an abbreviated new drug application (ANDA) has been filed by Chemo Research through its agent and...

October 25, 2022

Developments

PharmaJet gets USAID contract to evaluate needle-free delivery in polio shots

Closely-held PharmaJet received a multi-year, $1.5-million grant from the United States Agency for International Development (USAID) to evaluate the impact of intradermal vaccine administration using the company’s...

October 24, 2022

Developments

AUM Biosciences going public through merger with Mountain Crest Acquisition

Closely held AUM Biosciences, which is advancing a broad portfolio of precision oncology therapeutics, entered into a definitive business combination agreement with Mountain Crest Acquisition Corp. V (NASDAQ:MCAG). The...

October 21, 2022

Developments

Hepion Pharma food effect study with rencofilstat published

The peer-reviewed journal, Clinical Pharmacology in Drug Development, published the results of a clinical trial examining the effect of food on the oral bioavailability of Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug...

October 21, 2022

Developments

IntelGenx receives new U.S. patent on VersaFilm technology

IntelGenx Corp. (TSX:IGX; OTCQB:IGXT) received U.S. Patent No. 11,471,406 from the United States Patent and Trademark Office, with claims for modulating drug absorption in oral film dosage form designed for sublingual...

October 20, 2022

Developments

Jazz Pharma in license for Zymeworks’ HER2 zanidatamab

Jazz Pharmaceuticals (NASDAQ:JAZZ) inked an exclusive licensing agreement to acquire development and commercialization rights to Zymeworks’ (NYSE:ZYME) zanidatamab across all indications in the United States, Europe...

October 19, 2022

Developments

Ondine presents effective photodisinfection treatment research against MRSA

Ondine Biomedical (LON:OBI) presented new research at the Infection Prevention Society Conference in Bournemouth, UK showing that its Steriwave photodisinfection technology is highly effective against clinical MRSA...

October 19, 2022

Developments

LENZ Therapeutics posts positive Phase 2 presbyopia treatment data

Closely held LENZ Therapeutics reported positive topline results from its Phase 2 INSIGHT clinical trial of two investigational formulations of aceclidine to treat presbyopia, or farsightedness. Both LNZ100 (aceclidine)...

October 18, 2022

Developments

Comera reports favorable preclinical results of lead SQore excipient

Comera Life Sciences (NASDAQ:CMRA) reported favorable results from its recently completed SEQURUS-2 study. Together with the SEQURUS-1 study. the preclinical results showed that Comera’s caffeine-based SQore...

October 18, 2022

Subscribe